- Deciding on the best pharmacotherapy for advanced triple-negative breast cancer: expert guidance.
- Corvaja C, Taurelli Salimbeni B, Nicolò E, Puglisi F, Curigliano G.
- Expert Opin Pharmacother. 2022 Oct 21. doi: 10.1080/14656566.2022.2139176. Epub ahead of print.
- PMID: 36268855
- PubMed abstract
- Commentary
- Free Full Text
- Next-generation universal hereditary cancer screening: implementation of an automated hereditary cancer screening program for patients with advanced cancer undergoing tumor sequencing in a large HMO.
- Hoffman TL, Kershberg H, Goff J, Holmquist KJ, Haque R, Alvarado M.
- Fam Cancer. 2022 Oct 20. doi: 10.1007/s10689-022-00317-w. Epub ahead of print.
- PMID: 36261688
- PubMed abstract
- Germline Testing and Somatic Tumor Testing for BRCA1/2 Pathogenic Variants in Ovarian Cancer: What Is the Optimal Sequence of Testing?
- Kwon JS, Tinker AV, Santos J, Compton K, Sun S, Schrader KA, Karsan A.
- JCO Precis Oncol. 2022 Oct [20];6:e2200033. doi: 10.1200/PO.22.00033.
- PMID: 36265114
- PubMed abstract
- Source abstract
- SOLO-1 Data Support Use of Olaparib Maintenance to Achieve Long-Term Remission in BRCA+ Advanced Ovarian Cancer.
- Flaherty C, DiSilvestro PA.
- OncLive. 2022 Oct 20.
- Review. Interview.
- Free Full Text
Identifier: NCT01844986: Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy. (SOLO-1). (ClinicalTrials.gov . Accessed 2022 Oct 20.)
- Optimizing Therapy for Ovarian Cancer: Recent Data Highlights - Episode 5: Niraparib Maintenance Therapy in Ovarian Cancer: The PRIMA Trial.
- Monk BJ, Coleman RL, Westin SN, Birrer MJ.
- OncLive. Peer Exchange. 2022 Oct 20.
- Video. Review.
- Free Video
- Optimizing Therapy for Ovarian Cancer: Recent Data Highlights - Episode 6: The Rationale for PARP Inhibition plus IO in Ovarian Cancer.
- Monk BJ, Coleman RL, Westin SN, Birrer MJ.
- OncLive. Peer Exchange. 2022 Oct 20.
- Video. Review.
- Free video
- Combined inhibition of PARP and EZH2 for cancer treatment: Current status, opportunities, and challenges.
- Zhang X, Huo X, Guo H, Xue L.
- Front Pharmacol. 2022 Oct 3;13:965244. doi: 10.3389/fphar.2022.965244.
- PMID: 36263120
- PubMed abstract
- Review
- Free PMC article
- Free Full Text